MIRA
MIRA PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$0.81
+7.11%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.79
From 52W high−54.82%
Volume486759.00
Market cap$34.18M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.79
From 52W high
−54.82%
Volume
486759.00
Market cap
$34.18M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.8x
P/E (TTM)
—
RSI (14)
52.5
MomentumView details →
1D Return
+7.11%
YTD Return
−47.44%
SummaryUpdated Jun 1, 2026
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Baltimore, Maryland. The company went public in August 2023 and focuses on developing novel synthetic cannabinoid therapies for neurological and psychiatric conditions. MIRA was formerly known as MIRA1a Therapeutics, Inc. before its corporate restructuring and public listing. As a pre-revenue biotech company, MIRA is currently in the clinical development phase with its lead drug candidate targeting anxiety and cognitive decline associated with early-stage dementia.
Similar companies
Latest newsMore news →
MIRA Pharmaceuticals submitted the Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathy for IRB review at a leading cancer research institution following FDA review and comments.3d agoMIRA Pharmaceuticals announced positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs, advancing the non-opioid oral drug toward an IND filing.19d agoMIRA Pharmaceuticals announced positive toxicokinetic findings from a 7-day repeated-dose study of its obesity treatment candidate SKNY-1 in Beagle dogs, supporting advancement toward GLP toxicology studies and IND-enabling development.45d ago